Predictive. Prognostic. Personalized.

Vesta is Valar Labs’ genitourinary-focused portfolio of AI-powered pathology tests, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.

Risk StratifyTriplet PredictARPI Predict
Explore the Tests
Order Vesta
The Vesta Prostate portfolio

Comprehensive treatment insights for prostate cancer

Three complementary biomarkers for metastatic hormone-sensitive prostate cancer (mHSPC), read from existing H&E tissue. One reads the biology of the disease; two read whether a specific treatment intensification will pay off.

Runs on the existing H&E slide — no new biopsyResults in 2–3 days from specimen receiptBuilt on prospective randomized trial data
PrognosticFrame the risk
Vesta Prostate
Risk Stratify

How aggressive is this cancer, beyond PSA, Gleason, and volume?

Reads progression risk from tumor biology — a personalized prognostic score that complements the standard clinical and pathologic factors used to decide how intensively to treat.

Reports
Personalized prognostic score
PredictiveChoose the therapy
Vesta Prostate
Triplet Predict

Will adding docetaxel to ADT + ARPI help this patient?

Classifies disease as Favorable or Unfavorable Risk. Unfavorable-risk patients benefited from triplet therapy — adding docetaxel to ADT + ARPI — while Favorable-risk patients did not.

Reports
Favorable vs Unfavorable Risk
Vesta Prostate
ARPI Predict

Will ARPI intensification benefit this patient?

Reports the biomarker as present or absent: biomarker-present patients derived greater benefit from ARPI intensification — adding an ARPI to ADT — than biomarker-absent patients.

Reports
Greater vs less ARPI benefit
Validated in JCO Precision Oncology on randomized phase III trials

Vesta is designed to guide personalized care decisions for patients with GU cancers.

Our Computational Histology Artificial Intelligence (CHAI) platform uses standard pathology slides to purpose-build biomarkers that solve real clinical challenges. Results are delivered in days, not weeks, for informed, efficient care.

Built on Biology.

Novel Biomarkers

Valar Labs’ research team has developed and validated multiple unique Vesta biomarker signatures with data from thousands of patients with bladder and prostate cancers using histology features.

Expertly Trained AI

Valar Labs’ board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.

Fast, H&E-Based Testing

Leveraging existing tumor specimens, first-of-its-kind AI analyzes H&E pathology slides and returns actionable results in days for timely treatment decisions.

Are you a:

Patient
Patient

Learn how the Vesta Prostate tests can help guide personalized treatment decisions for you or a loved one diagnosed with metastatic hormone-sensitive prostate cancer.

Learn more
Healthcare Professional
Healthcare Professional

Discover how AI-powered pathology can help you make more informed treatment intensification decisions for your mHSPC patients, going beyond volume and timing.

Get in touch
Learn More
Industry Partner
Industry Partner

Explore partnership opportunities in precision oncology diagnostics and AI-powered computational pathology solutions for GU cancers.

Work with us

Frequently asked questions about Vesta

What is Vesta Prostate?

Vesta Prostate is a portfolio of three AI-powered pathology tests for hormone-sensitive prostate cancer, all read from a single H&E slide. Risk Stratify assesses prognosis from tumor biology; Triplet Predict identifies patients likely to benefit from adding docetaxel to ADT + ARPI; and ARPI Predict identifies patients likely to derive greater benefit from ARPI intensification (adding an ARPI to ADT). Together they help physicians make personalized treatment-intensification decisions that go beyond traditional clinical variables.

What specimen is required?

The test requires an H&E pathology slide—the most recently available tissue representative of the highest Gleason grade. Acceptable tissue sources include prostate, lymph node, or bone. Valar Labs leverages existing tumor specimens, so no additional biopsy is needed.

How long does it take to get results?

Expect results within 2–3 days of sample receipt. Reports are delivered via the secure online portal, and your clinic team is alerted when results are ready.

How do I order a test?

Your clinic team submits basic patient information via our secure online portal. Valar Labs then coordinates directly with pathology to request the specimen. No complex paperwork is required.

What does the report tell me?

Each test returns a focused result. Risk Stratify reports a personalized prognostic score based on tumor biology. Triplet Predict classifies disease as Favorable or Unfavorable Risk — Unfavorable-risk patients benefited from adding docetaxel (triplet) to ADT + ARPI, while Favorable-risk patients did not. ARPI Predict reports the biomarker as present or absent — biomarker-present patients derived greater benefit from ARPI intensification (adding an ARPI to ADT). Together they help guide personalized treatment-intensification decisions.

What technology powers Vesta?

Vesta is built on Valar Labs’ Computational Histology Artificial Intelligence (CHAI) platform, trained on 500,000+ expert pathologist annotations. The platform analyzes H&E pathology slides using novel biomarker signatures validated with data from thousands of patients.

Is there clinical evidence supporting Vesta?

Yes. The Vesta Prostate biomarker signatures were developed and validated using data from multiple pivotal prospective randomized controlled trials.

Peer-Reviewed Research

See the Evidence

Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials

July 2026

Development and validation of computational histology artificial intelligence (CHAI)-powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials

March 2026

Ready for Vesta?

Join leading physicians using Vesta computational histology biomarkers to guide personalized care.

Get in touch

1. Sweeney CJ, Krishna V, Krishna V, et al. Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials. JCO Precis Oncol. 2026;10:e2600321. 2. Agarwal N, Gebrael G, Swami U, et al. J Clin Oncol 44, 231 (2026).